Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Cassia Capital Partners LLC

Cassia Capital Partners LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 621 shares of the biopharmaceutical company’s stock after buying an additional 32 shares during the quarter. Cassia Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $545,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Sunbelt Securities Inc. acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. Sutton Wealth Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $40,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 1.7 %

Regeneron Pharmaceuticals stock traded down $15.88 during midday trading on Thursday, reaching $920.32. 617,049 shares of the stock traded hands, compared to its average volume of 489,499. The company has a 50-day simple moving average of $959.12 and a two-hundred day simple moving average of $887.99. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The firm has a market cap of $101.01 billion, a PE ratio of 26.94, a price-to-earnings-growth ratio of 2.74 and a beta of 0.11. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same period last year, the business posted $10.96 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock worth $13,124,641 in the last three months. 8.83% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on REGN. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Finally, Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $968.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.